Book · Julian R. Sterling
Forecasts, Take-or-Pay, Quality, Failed Batches, Supply Assurance and Termination in Contract Manufacturing, Clause by Clause, With a Fully Worked Case
Apple Books Google Play PDF edition
A biopharma manufacturing and supply agreement is only half of the paper. The quality agreement that sits beside it decides who releases a batch, who investigates a deviation and who approves a change, while the supply agreement decides what is ordered, what it costs and who pays when a batch fails. This guide reads the two documents side by side, clause by clause, for a legal or contracts manager at a biotech or mid-sized pharma company, a technical operations or CMC lead, a supply chain or procurement manager, a biotech finance director, a lawyer or commercial manager at a contract manufacturer, an analyst who reads a supply agreement filed as an exhibit to a 10-K or an S-1, and a junior life sciences lawyer.
How to Read a Biopharma Manufacturing and Supply Agreement goes through why the supply agreement and the quality agreement are two documents and which one prevails; scope, the project plan and technology transfer; rolling forecasts, firm orders, capacity reservation and take-or-pay shortfall fees; batch prices, raw materials, yield and annual price adjustments; batch release, deviations and change control, read against the FDA's current good manufacturing practice rules and its 2016 guidance on quality agreements; specifications, rejected batches and who pays for a failed batch; safety stock, back-up manufacturers and step-in rights; process improvements and who owns them; regulatory filings, inspections and audits; liability caps, recalls and indemnities; and term, termination and transfer out. One fictional antibody and one fictional contract manufacturer are followed from technology transfer to the fifth year of supply.
What is inside:
The example clauses, the case, its companies, product, people, batches, prices, yields, fees, quantities and dates are written for this book; the figures are fictional teaching assumptions, not market data or forecasts, and no clause is taken from any real agreement or form. The book covers contract manufacturing of biologic drugs under United States rules; other countries are not covered. Regulations, guidance and filed agreements are paraphrased and cited as of the dates given in the book. This book is for education only and is not legal, regulatory, investment, tax or accounting advice. No company, manufacturer, agency or law firm has reviewed or endorsed it.
Related titles. The full list is on the author page.